Shenzhen Lifotronic Technology Co., Ltd. (688389)
- 11.31
- -0.03-0.26%
Shenzhen Lifotronic Technology Co., Ltd. (688389) News
Pumen Technology (688389.SH): Obtained Two Medical Device Registration Certificates
Gelonghui, July 20 — Pumedic Healthcare (688389.SH) announced that the company recently received two Certificates of Medical Device Registration (In Vitro Diagnostic Reagents) issued by the Guangdong Provincial Medical Products Administration. The certificates are for the Thrombomodulin (TMSTAT) Assay Kit and the Total Type I Collagen N-terminal Propeptide (Total-P1NP) Assay Kit, both valid until July 16, 2031.
Pum Tech (688389.SH): Company's product receives IVDR CE certification
Gelonghui, July 8 — Pumantech (688389.SH) announced that 29 of its electrochemiluminescence reagent products and one hemoglobin chromatography column have received IVDR CE certification issued by TÜV SÜD, a European Union Notified Body. The new EU In Vitro Diagnostic Medical Devices Regulation (IVDR, EU 2017/746) has replaced the previous EU In Vitro Diagnostic Medical Devices Directive (IVDD, 98/79/EC) to regulate in vitro diagnostic medical devices in the EU market. To date, the company has cumulatively obtained IVDR CE certification for 82 electrochemiluminescence reagent products. According to the EU
Pumen Technology (688389.SH) announced that its actual controller plans to increase holdings of the company's shares by an amount between RMB 10 million and RMB 30 million.
Pumeng Technology (688389.SH) announced that Liu Xiancheng, the company's controlling shareholder, actual controller, and chairman of the board, intends to purchase shares of the company through centralized bidding transactions via the Shanghai Stock Exchange trading system, using his own funds, within six months from the date of disclosure of the share purchase plan. The proposed amount for the share purchase is no less than RMB 10 million (inclusive) and no more than RMB 30 million (inclusive).
Express News | Pum Tech: Obtained Medical Device Registration Certificate for Glycated Hemoglobin Assay Kit
Primedeas Biotech Co., Ltd. (SHA: 688389): Zhai Roumei Resigns as Securities Affairs Representative
Gelonghui, June 9 — Primedeq Technology Co., Ltd. (SHA: 688389) announced that the company's board of directors recently received a written resignation letter from Ms. Zhai Roumei, the company's securities affairs representative. Ms. Zhai Roumei has applied to resign from her position as securities affairs representative for personal reasons. The resignation takes effect upon delivery to the company's board of directors. Following her resignation, Ms. Zhai will no longer hold any position at the company, and her departure will not affect the normal operation of the company's relevant activities.
Pumen Technology (688389) 2025 Annual Report and 2026 Q1 Report Commentary: Short-Term Earnings Under Pressure; Platform Strategy and Overseas Expansion Continue to Advance
Item: The company released its 2025 annual report and 2026 first-quarter report. Full-year 2025 revenue was RMB 1.038 billion (-9.60%), attributable net profit was RMB 184 million (-46.66%), and non-recurring-item-adjusted attributable net profit was RMB 163 million.
Primed Biotech (688389): Domestic business faces short-term pressure, while overseas markets show strong growth.
The company's performance declined in the short term. For the full year of 2025, the company reported revenue of RMB 1.038 billion (a year-over-year decrease of 9.60%, unless otherwise stated), net profit attributable to shareholders of RMB 184 million (down 46.66%), and net profit attributable to shareholders excluding non-recurring gains and losses of RMB 163 million (
Pum Tech (688389.SH) 2025 Annual Dividend Distribution: RMB 0.282 per share
Gelonghui, May 21 — Pum Tech (688389.SH) announced its 2025 annual profit distribution implementation notice, stating that the company intends to distribute profits for 2025 based on the total number of shares registered on the record date of the profit distribution. The company will pay a cash dividend of RMB 2.82 per 10 shares (tax inclusive) to all shareholders, with no bonus shares issued and no capital reserve conversion into additional share capital. The record date for this profit distribution is May 27, 2026, and the ex-dividend date is May 28, 2026.
Pumen Technology (688389.SH): The company has applied AI skin detection technology to products such as semiconductor laser hair removal devices.
Gelonghui, May 13th ┃ Pumeng Technology (688389.SH) stated on the investor interaction platform that Pumeng Technology actively embraces AI technological innovation and is committed to integrating advanced intelligent solutions into product development and services. This is specifically reflected in the following aspects: (1) In the field of in vitro diagnostics, the company's fully automated chemiluminescence immunoassay analyzers eCL8600 and eCL8800 series, based on the electrochemiluminescence immunoassay technology platform, use AI algorithms to achieve precise identification of barcodes and container types, significantly improving detection efficiency and accuracy; in 2025, the company will leverage its 'intelligent differentiation of hemoglobin'...
Pumen Technology (688389.SH): Shareholder Qiu Liang plans to reduce no more than 1 million shares of the company.
Gelonghui, May 11th - Pumen Technology (688389.SH) announced that due to personal financial needs, Mr. Qiu Liang intends to reduce his holdings of the company's shares through centralized bidding within 3 months after 15 trading days from the date of this reduction plan announcement. The number of shares to be reduced will not exceed 1 million shares, accounting for no more than 0.24% of the company's total share capital and no more than 25% of the total number of shares he held before the reduction. The reduction price will be determined based on the market price.
Pumen Technology (688389): Q1 2026 Growth Inflection Point Emerges, Overseas and Consumer Businesses Perform Strongly
Event: The company released its annual report for 2025 and the first-quarter report for 2026. In 2025, it achieved revenue of 1.038 billion yuan (year-over-year decrease of 9.60%) and a net profit attributable to shareholders of 184 million yuan (year-over-year decrease of 46.66%).
Express News | Pumen Technology: Obtains Medical Device Registration Certificate for Focused Ultrasound Skin Treatment Instrument
Pumen Technology (688389): Domestic operations affected by policy, but overseas experiencing rapid growth.
The company's revenue/net profit attributable to shareholders/non-GAAP net profit attributable to shareholders for 2025 amounted to RMB 1.038/1.84/1.63 billion, representing a year-on-year decrease of 9.6%/46.7%/50.3%, consistent with the company's earnings flash report. First-quarter 2026 revenue...
Pumen Technology (688389): Strong growth in home-use products, continued increased investment in core business
Key investment highlights: Event: The company released its financial results for 2025 and the first quarter of 2026. In 2025, it achieved revenue of 1.038 billion yuan (yoy -9.60%) and net profit attributable to shareholders of 184 million yuan (yoy -
Pumen Technology: 2025 Annual Report of Shenzhen Pumen Technology Co., Ltd.
Pumen Technology: Shenzhen Pumen Technology Co., Ltd. First Quarter Report for 2026
Pumen Technology: Summary of the 2025 Annual Report of Shenzhen Pumen Technology Co., Ltd.
2025 Annual Report of Shenzhen Pumen Technology Co., Ltd.
Summary of the 2025 Annual Report of Shenzhen Pumen Technology Co., Ltd.
Shenzhen Pumen Technology Co., Ltd. First Quarter Report for 2026